Shares of healthcare technology company Masimo (NASDAQ:MASI) are nosediving today after investors were disappointed with its preliminary top-line numbers for the second quarter.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Consolidated revenue for the quarter is now expected to hover between $453 million and $457 million. In comparison, analysts were expecting revenue of $528.7 million for the period.
While healthcare revenue is anticipated between $280 million to $282 million, non-healthcare revenue is seen landing between $173 million and $175 million. Masimo is witnessing large order delays in the healthcare segment along with challenges in the conversion of new customers. Additionally, challenges in the non-healthcare segment continue to persist with tepid demand now extending from lower-end to higher-end audio categories as well.
Consequently, Masimo is now taking initiatives to streamline costs and more details are anticipated on August 8 when Masimo is slated to announce second quarter numbers. The Street largely expects EPS for the quarter at $0.93.
The company currently expects to decrease the lower end of its full-year revenue outlook for the healthcare vertical to $1.30 billion from $1.45 billion. It also expects to decrease the revenue outlook for the non-healthcare vertical to a range of $800 million to $850 million from the prior range between $965 million and $995 million.
Overall, the Street has a $174.17 consensus price target on Masimo alongside a Moderate Buy consensus rating. Short interest in the stock is currently inching toward 6%.
Read full Disclosure